Association of circulating C-reactive protein and interleukin-6 with longevity into the 80s and 90s: The Rancho Bernardo Study.

循环 C 反应蛋白和白细胞介素-6 与 80 多岁和 90 多岁寿命的关联:兰乔贝尔纳多研究

阅读:7
作者:Wassel Christina L, Barrett-Connor Elizabeth, Laughlin Gail A
CONTEXT: Few studies have examined whether the inflammatory markers IL-6 and C-reactive protein (CRP) are associated with exceptional longevity. OBJECTIVE: Our objective was to determine the association of serum CRP and IL-6 with adult lifespan. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, population-based study of 610 men and 743 postmenopausal women, mean age 73 yr, who had serum IL-6 and CRP measurements at baseline (1984-1987) and who were followed for mortality for up to 23 yr (through 2008). Participants must have been old enough at baseline (57 yr) to have the potential to achieve age 80 during follow-up. MAIN OUTCOME MEASURES: Relative survival time and age at death (lifespan) were assessed. RESULTS: During follow-up, overall mortality was 69%. After adjustment for cardiovascular disease risk factors, in men, each sd increase in IL-6 was associated with a 15% decrease in survival time and 0.94-yr shorter lifespan (P < 0.001); corresponding values for CRP were a 12% decrease in survival time and a 1.00-yr reduction in lifespan (P < 0.001). Among women not using estrogen therapy (n = 532), survival time decreased 7% per sd higher IL-6 and lifespan was 1.35 yr shorter (P < 0.001). IL-6 was not related to lifespan among women using estrogen. CRP levels were not significantly associated with survival time or lifespan in women regardless of estrogen status. CONCLUSIONS: Higher levels of inflammatory markers predicted reduced survival time and shorter lifespan among older men, whereas only IL-6 was associated with longevity in postmenopausal women and only among those not using estrogen.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。